Nevertheless, a combined therapy for activation of α7 nAChR to reduce inflammation and inhibition of α5 nAChR or TRPC3 channels to reduce airway smooth muscle cell proliferation might represent a promising therapeutic approach for COPD. The gene discussed is CHRNA7; the disease is chronic obstructive pulmonary disease.